Galapagos(GLPG) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total operating profit from continuing operations amounted to EUR 295.1 million in 2025, compared to an operating loss of EUR 188.3 million in 2024, primarily due to the release of EUR 1,069 million in deferred income related to Gilead [9][10] - Financial investments in cash and cash equivalents totaled EUR 2,998 million on December 31, 2025, down from EUR 3,317.8 million on December 31, 2024 [12] - The company expects to have approximately EUR 2.775 billion to EUR 2.85 billion in cash equivalents and financial investments at December 31, 2026 [15] Business Line Data and Key Metrics Changes - The decision to wind down cell therapy activities resulted in operating expenses of EUR 399.8 million, including an impairment of EUR 228.1 million and severance costs of EUR 33.3 million [11] - The strategic reorganization related to the small molecule business announced in 2025 incurred costs of EUR 124.8 million [11] Market Data and Key Metrics Changes - The company has transitioned a significant portion of its cash holdings to US dollars, now holding approximately 72% in USD and 28% in euros, reflecting a strategic shift based on expected business development activities [12][49] Company Strategy and Development Direction - The company is focused on transforming its strategic direction away from cell therapy, aiming for long-term value creation with a strong foundation and approximately EUR 3 billion in cash [4][8] - The management team has been restructured to include leaders with extensive business development expertise, aiming to create significant shareholder value [5] - Collaboration with Gilead is viewed as a key strategic advantage, enhancing the company's ability to pursue transformative business development opportunities [6][7] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for business development opportunities, particularly in the immunology and oncology sectors, while maintaining a disciplined approach to capital allocation [19][20] - The company anticipates being cash flow neutral to positive by the end of 2026, despite ongoing restructuring costs [14][52] Other Important Information - The company plans to complete the wind down of cell therapy activities by the end of Q3 2026, with an expected one-time restructuring cash impact of EUR 125 million to EUR 175 million in 2026 [13] - The annual report is expected to be filed near the end of March 2026, providing additional information to stakeholders [57] Q&A Session Summary Question: Update on business development focus and Gilead agreement - Management confirmed the strategy remains focused on de-risking late-stage clinical assets, particularly in immunology and oncology, without setting a specific deadline for deals [19][20] Question: Thoughts on GLPG3667 development versus out-licensing - Management maintains a high bar for all assets, including GLPG3667, and is exploring partnerships to accelerate development while ensuring capital efficiency [25][27] Question: Capital allocation and Gilead partnership impact - The company has EUR 3 billion in capital, which will be allocated for acquisitions and development expenses, with Gilead potentially contributing to deal terms and development costs [30][33] Question: Expectations for operating income breakeven - Management expects to be cash flow neutral or positive by year-end 2026, though predicting exact timing for costs is challenging [51][52]